Market Report, "South Korea Pharmaceuticals & Healthcare Report Q4 2013", published
While we continue to forecast steady expansion in terms of South Korea's pharmaceutical market values, we note that operating conditions for innovative drugmakers will remain challenging. Indeed, in its 2013 submission to the United States Trade Representative (USTR), the US trade association - Pharmaceutical Research and Manufacturers of America (PhRMA) recommended that South Korea be added to its 'watch list' of countries in 2013. PhRMA's main areas of concern include the lack of effective patent enforcement, vague data protection regulations...
View full press release